Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
Hemodynamic management of patients with cardiogenic shock centers on vasopressors, inotropes, and mechanical circulatory devices. With respect to inotropic medications, there is little data...
Approximately 2 million patients present each year to EDs in the United States for acute asthma exacerbations. Of these, up to 50,000 may require...
ED Pharmacist extraordinaire Jill Logan joins CCPEM to discuss the use of high-dose nitroglycerin in patients with acute cardiogenic pulmonary edema. Is it safe? ...
